# Progress Note 01 — Initial plan

> **SYNTHETIC RECORD, NOT A REAL MEDICAL RECORD**

- Patient: Judy Garland (real historical name used in a fictional teaching record)
- Synthetic MRN: HR-ML005-SYN-TD
- Date: 1955-06-22
- Fictional facility: St. Posthumous Health Center
- Fictional author: Margaret Ellsworth-Diaz, MD
- Calendar frame: true historical dates (modern content is anachronistic)

> True-date frame: synthetic events are moved into the patient's historical lifetime. Codes, instruments, and treatments remain modern and are anachronistic.

## Subjective

The patient participates in this fictional visit for establishing primary care for long-term prescribed sleeping pills and stimulants that began in adolescence: a nonjudgmental assessment, a prescription drug monitoring program review, sleep, mood, anxiety and safety, nutrition, and contraception three months after childbirth. **S**

## Objective

Hemoglobin: 12.3 g/dL; MCV: 86 fL; Platelets: 284 10*3/uL; Ferritin: 24 ng/mL; Sodium: 139 mmol/L; Potassium: 4.1 mmol/L; Creatinine: 0.66 mg/dL; eGFR (CKD-EPI 1950): 119 mL/min/1.73 m²; Glucose: 82 mg/dL; AST: 21 U/L; ALT: 18 U/L; GGT: 24 U/L; TSH: 1.9 mIU/L; DAST-10: 6; AUDIT-C: 2; PHQ-9: 14; GAD-7: 13. All results are synthetic.

BP 128/84 mmHg; pulse 98 bpm; respirations 16/min; temperature 36.8 °C; oxygen saturation 99% on room air; weight 46.5 kg; BMI 20.4 kg/m². All vital signs are synthetic.

## Assessment

Active problems: Sedative, hypnotic, or anxiolytic use disorder (barbiturate), moderate, with physiological dependence; began with sleeping pills given in adolescence; synthetic modern episode linked to her documented lifelong dependence on prescribed sleeping pills; Stimulant use disorder (prescribed amphetamine), mild; began with stimulants given in adolescence for weight and energy; synthetic modern episode linked to her documented pep pills; Chronic insomnia disorder, long-standing, with sleep tied to sleeping pills since adolescence; Contraception three months after childbirth while starting an enzyme-inducing drug: injectable progestin chosen because barbiturates, including any used for the withdrawal, weaken contraceptive pills, patches, rings and implants; Major depressive disorder, single episode, moderate, with anxious distress; Mood Disorder Questionnaire negative and no history of mania or hypomania. Strengths and supports remain part of the care plan. **S**

## Medication changes

- Started: Secobarbital 100 mg oral capsule, two capsules (200 mg) at bedtime; prescribed elsewhere for years; continued by this clinic at the verified dose, seven days at a time, until a supervised withdrawal is planned with addiction medicine **S**
- Started: Dextroamphetamine 10 mg oral tablet, one tablet each morning; no extra doses; prescribed elsewhere for weight and energy **S**
- Started: Sertraline 25 mg oral tablet, one tablet daily **S**
- Started: Medroxyprogesterone acetate 150 mg/mL injection, 150 mg into the muscle every 13 weeks **S**

## Plan

- Safe prescribing of controlled drugs: one prescriber and one pharmacy, a prescription drug monitoring program check before every controlled-substance prescription, a written shared treatment agreement, urine drug testing explained as part of care, seven-day supplies at first, a locked box, and take-back of unused capsules. Guideline: Joint Clinical Practice Guideline on Benzodiazepine Tapering: Considerations When Risks Outweigh Benefits (2025); Prescription Drug Monitoring Programs (PDMPs) (2026) **S**
- Addiction medicine consultation to confirm the diagnoses, plan a safe barbiturate withdrawal and taper, and advise on stopping the stimulant. Guideline: Joint Clinical Practice Guideline on Benzodiazepine Tapering: Considerations When Risks Outweigh Benefits (2025); The ASAM Clinical Practice Guideline on Alcohol Withdrawal Management (2020); The ASAM/AAAP Clinical Practice Guideline on the Management of Stimulant Use Disorder (2024) **S**
- Insomnia: cognitive behavioral therapy for insomnia as first-line treatment, adapted to late performances (a fixed wake time, a wind-down routine after shows, sleep restriction only after the taper is stable), with a sleep diary; no new hypnotic. Guideline: Clinical Practice Guideline for the Pharmacologic Treatment of Chronic Insomnia in Adults: An American Academy of Sleep Medicine Clinical Practice Guideline (2017); Management of Chronic Insomnia Disorder in Adults: A Clinical Practice Guideline From the American College of Physicians (2016) **S**
- Depression and anxiety: PHQ-9 and GAD-7 at each visit, sertraline, weekly psychotherapy, the Mood Disorder Questionnaire before the antidepressant, a structured safety assessment with a written safety plan, means safety and the 988 Suicide & Crisis Lifeline, and safety review at every visit. Guideline: Depression and Suicide Risk in Adults: Screening (2023); VA/DoD Clinical Practice Guideline for Assessment and Management of Patients at Risk for Suicide (2024); CMID: Clinical Monitoring Intelligence Database, depression, bipolar, and mood disorders monograph (2026) **S**
- Nutrition and weight without stigma: regular meals and snacks around rehearsals, a dietitian visit, no weight-loss target and no dieting drugs, and screening for disordered eating. Guideline: The ASAM/AAAP Clinical Practice Guideline on the Management of Stimulant Use Disorder (2024) **S**
- Contraception that barbiturates do not weaken: medroxyprogesterone injection every 13 weeks, after a negative pregnancy test, with an intrauterine device as an alternative. Guideline: U.S. Medical Eligibility Criteria for Contraceptive Use, 2024 (2024) **S**
- Naloxone not prescribed: she takes no opioid, has no opioid prescription in the monitoring program, her urine test shows no opioids or fentanyl, and all her pills come from a pharmacy; naloxone does not reverse a barbiturate overdose. To be offered at once if an opioid is ever prescribed or any pill comes from outside a pharmacy. Guideline: The ASAM/AAAP Clinical Practice Guideline on the Management of Stimulant Use Disorder (2024); Prescription Drug Monitoring Programs (PDMPs) (2026) **S**
- Work: taper steps scheduled away from major performances, a written plan for late nights and travel, and letters she controls. Guideline: Joint Clinical Practice Guideline on Benzodiazepine Tapering: Considerations When Risks Outweigh Benefits (2025) **S**
